Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

There’s a precedent for combining the two checkpoint inhibitor mechanisms in HCC, as Bristol-Myers Squibb claimed FDA approval last month for the combination of its PD-1 drug Opdivo (nivolumab ...